Igor Feldman

Statistics

Publications

Citations

2.3K

H-Index

Active since

2003

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

Moderna Therapeutics (United States)

Epizyme (United States)

Harvard University

Columbia University

Igor Feldman is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicine, cancer therapeutics, and radiation oncology.

ORCID

Top concepts

MedicineOncologyPathologyCancer TherapySystems BiologyRadiation OncologyGeneticsImmunologyLung CancerPharmacology

Publications per year

2003–2024

Publications

Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study

Jeffrey S. Weber, Matteo S. Carlino, Adnan Khattak et al. · The Lancet · 2024 · 598 citations

Medicine, Melanoma, Immunology +7

An Unbiased Oncology Compound Screen to Identify Novel Combination Strategies

Jennifer O’Neil, Yair Benita, Igor Feldman et al. · Molecular Cancer Therapeutics · 2016 · 410 citations

Drug Target, Combination Drug Therapy, Tumor Biology +17

Network properties of genes harboring inherited disease mutations

Igor Feldman, Andrey Rzhetsky, Dennis Vitkup · Proceedings of the National Academy of Sciences · 2008 · 294 citations · Full text

Network Properties, Genetics, Genetic Epidemiology +18

Preclinical Evaluation of the WEE1 Inhibitor MK-1775 as Single-Agent Anticancer Therapy

Amy D. Guertin, Jing Li, Yaping Liu et al. · Molecular Cancer Therapeutics · 2013 · 169 citations

Selective Killing of SMARCA2- and SMARCA4-deficient Small Cell Carcinoma of the Ovary, Hypercalcemic Type Cells by Inhibition of EZH2: <i>In Vitro</i> and <i>In Vivo</i> Preclinical Models

Elayne Chan-Penebre, Kelli Armstrong, Allison E. Drew et al. · Molecular Cancer Therapeutics · 2017 · 163 citations

1–5 of 13